MAP2K7 and melanoma: The effect of BRAF/MEK inhibitors on the expression of CD47 was confirmed in additional two BRAFV600E (IgR3 and Sk-Mel-28) and two wild-type BRAF (ME1007 and ME4405) melanoma cells lines treated with vemurafenib and trametinib, respectively (Supplementary Figure 1B).